The Accelerating Medicines Partnership in Common Metabolic Diseases (AMP-CMD®) is a public-private partnership to identify drivers of common metabolic diseases, including nonalcoholic steatohepatitis, chronic kidney disease, obesity, atherosclerotic cardiovascular disease and heart failure, type 2 diabetes/prediabetes, autoimmune diabetes, and inflammation. AMP-CMD supports the generation and analysis of genetic association results, epigenomic annotations, and functional studies, and the representation of these results in the Common Metabolic Diseases Knowledge Portal.
The funding for AMP-CMD from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) includes $500,000 annually for an Opportunity Pool (OP) to support research aligned with the consortium's goals. This funding opportunity is open to applicants both within and outside of the AMP-CMD consortium; researchers who receive OP support will become members of AMP-CMD.
In this round of OP funding, applications are due September 1, 2022. To apply, start by reading the Funding Opportunity Announcement and then consult the Opportunity Pool Handbook for details on how to apply. Questions? Please email firstname.lastname@example.org.